a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Koenig, Kristin L. [1 ]
Brame, Colin [2 ]
Sher, Steven [1 ]
Beaver, Larry [1 ]
Cempre, Casey B. [1 ]
Williams, Katie [1 ]
Purcell, Matthew [2 ]
Harrington, Bonnie [3 ]
Chen, Yi [4 ]
Tan, Felai [4 ]
Anthony, Stephen P. [4 ]
Chen, Yu [4 ]
Shen, Yue [4 ]
Byrd, John C. [5 ]
Lapalombella, Rosa [6 ]
机构：
[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH USA
[2] Ohio State Univ, Columbus, OH USA
[3] Charles River Labs, Wilmington, NC USA
[4] Newave Pharmaceut Inc, Pleasanton, CA USA
[5] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[6] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol, Columbus, OH USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LP-118
引用
收藏
页码：9068 / 9069
页数：2
相关论文
共 50 条
  • [41] A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl
    Deng, Jing
    Mao, Tingting
    Huang, Xiaojing
    Rui, Li
    Wang, Guangfeng
    Fang, Douglas D.
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2019, 134
  • [42] SPG6 supports development of acute myeloid leukemia by regulating BMPR2-Smad-Bcl-2/Bcl-xl signaling
    Chen, Jinliang
    Li, Chunling
    Zhan, Renhui
    Yin, Yancun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 501 (01) : 220 - 225
  • [43] Concurrent targeting Bcl-2/Bcl-xL and MDM2 as a new therapeutic strategy for acute leukemia
    Hoffman-Luca, C. Gianna
    McEachern, Donna
    Ziazadeh, Daniel
    Zhao, Yu-Jun
    Sun, Wei
    Debussche, Laurent
    Wang, Shaomeng
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [44] Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
    Yoshihito Morimoto
    Kimihiko Takada
    Osamu Takeuchi
    Kazuhiro Watanabe
    Masayoshi Hirohara
    Tomoyuki Hamamoto
    Yutaka Masuda
    Molecular and Cellular Biochemistry, 2020, 472 : 187 - 198
  • [45] Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
    Morimoto, Yoshihito
    Takada, Kimihiko
    Takeuchi, Osamu
    Watanabe, Kazuhiro
    Hirohara, Masayoshi
    Hamamoto, Tomoyuki
    Masuda, Yutaka
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 472 (1-2) : 187 - 198
  • [46] Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas
    Gobé, G
    Rubin, M
    Williams, G
    Sawczuk, I
    Buttyan, R
    CANCER INVESTIGATION, 2002, 20 (03) : 324 - 332
  • [47] Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL
    Mekori, YA
    Gilfillan, AM
    Akin, C
    Hartmann, K
    Metcalfe, DD
    JOURNAL OF CLINICAL IMMUNOLOGY, 2001, 21 (03) : 171 - 174
  • [48] Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
    Pena, JC
    Thompson, CB
    Recant, W
    Vokes, EE
    Rudin, CM
    CANCER, 1999, 85 (01) : 164 - 170
  • [49] Human Mast Cell Apoptosis Is Regulated Through Bcl-2 and Bcl-XL
    Yoseph A. Mekori
    Alasdair M. Gilfillan
    Cem Akin
    Karin Hartmann
    Dean D. Metcalfe
    Journal of Clinical Immunology, 2001, 21 : 171 - 174
  • [50] Bcl-XL and Bcl-2 expression in squamous cell carcinoma of the head and neck
    Budach, W
    STRAHLENTHERAPIE UND ONKOLOGIE, 1999, 175 (10) : 533 - 534
12345